REaCT: REthinking Clinical Trials

REaCT-TEMPO

REaCT-TEMPO	Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance. Principal Investigator(s): Dr. Marie-France Savard
ClinicalTrials.gov: NCT05754528
This study is for patients with early stage breast cancer that are starting endocrine therapy. This is a pragmatic open-label, randomized clinical trial to establish if a dose-frequency escalation strategy of administering endocrine therapy will improve side effects and benefits in early stage breast cancer patients. Different strategies to help reduce side effects have been studied but none have clearly been shown to help patients take their hormonal therapy as prescribed by their physician. The aim of this study is to determine if taking hormone therapy every other day for one month and then daily (“dose-frequency escalation”) as opposed to daily from the start will help improve the tolerability and adherence to endocrine therapy. Many physicians start patients on lower doses of tablets at the start of treatment and there is supporting evidence from other trials showing this is an effective strategy with no added risk.
Sites: The Ottawa Hospital Thunder Bay
Tags: Early stage Breast Cancer